337 related articles for article (PubMed ID: 28589387)
21. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
López-Knowles E; Hernández S; Malats N; Kogevinas M; Lloreta J; Carrato A; Tardón A; Serra C; Real FX
Cancer Res; 2006 Aug; 66(15):7401-4. PubMed ID: 16885334
[TBL] [Abstract][Full Text] [Related]
22. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.
Bakkar AA; Wallerand H; Radvanyi F; Lahaye JB; Pissard S; Lecerf L; Kouyoumdjian JC; Abbou CC; Pairon JC; Jaurand MC; Thiery JP; Chopin DK; de Medina SG
Cancer Res; 2003 Dec; 63(23):8108-12. PubMed ID: 14678961
[TBL] [Abstract][Full Text] [Related]
23. Plasmacytoid variant of urothelial carcinoma: a report of a rare case.
Demellawy DE; Ahmed AD; Bora B; Bonin M
Pathol Res Pract; 2012 Sep; 208(9):561-4. PubMed ID: 22854197
[TBL] [Abstract][Full Text] [Related]
24. Molecular basis of urinary bladder cancer.
Al Hussain TO; Akhtar M
Adv Anat Pathol; 2013 Jan; 20(1):53-60. PubMed ID: 23232572
[TBL] [Abstract][Full Text] [Related]
25. [Urothelial carcinoma. Does surgical pathology learn from molecular pathology?].
Hofstädter F
Pathologe; 2008 Nov; 29 Suppl 2():145-8. PubMed ID: 18836723
[TBL] [Abstract][Full Text] [Related]
26. Micropapillary variant of transitional cell carcinoma of the urinary bladder: a report of three cases with cytologic diagnosis in urine specimens.
Ylagan LR; Humphrey PA
Acta Cytol; 2001; 45(4):599-604. PubMed ID: 11480725
[TBL] [Abstract][Full Text] [Related]
27. Coexistence of papillary and nodular carcinomas in the urinary bladder.
Kakizoe T; Matsumoto K; Tobisu K; Takai K; Teshima S; Kishi K
Jpn J Clin Oncol; 1987 Jun; 17(2):179-86. PubMed ID: 3613141
[TBL] [Abstract][Full Text] [Related]
28. The relationship between non-invasive papillary lesions and invasive bladder carcinoma.
Brawn PN
Cancer; 1984 Aug; 54(4):620-3. PubMed ID: 6744201
[TBL] [Abstract][Full Text] [Related]
29. The Emerging Molecular Landscape of Urothelial Carcinoma.
Solomon JP; Hansel DE
Surg Pathol Clin; 2016 Sep; 9(3):391-404. PubMed ID: 27523968
[TBL] [Abstract][Full Text] [Related]
30. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses.
Obermann EC; Junker K; Stoehr R; Dietmaier W; Zaak D; Schubert J; Hofstaedter F; Knuechel R; Hartmann A
J Pathol; 2003 Jan; 199(1):50-7. PubMed ID: 12474226
[TBL] [Abstract][Full Text] [Related]
31. Coexistence of Malakoplakia and Papillary Urothelial Carcinoma of the Urinary Bladder.
Lee SL; Teo JK; Lim SK; Salkade HP; Mancer K
Int J Surg Pathol; 2015 Oct; 23(7):575-8. PubMed ID: 26194600
[TBL] [Abstract][Full Text] [Related]
32. Renal cell carcinoma with concurrent urothelial carcinoma of urinary bladder and non-Hodgkin lymphoma.
Müller D; Tomasović-Loncarić C; Galeic-Iljubanović D; Heinzl R; Savić I; Marusić P
Coll Antropol; 2012 Sep; 36(3):1049-52. PubMed ID: 23213971
[TBL] [Abstract][Full Text] [Related]
33. H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases.
Castillo-Martin M; Collazo Lorduy A; Gladoun N; Hyun G; Cordon-Cardo C
J Pediatr Urol; 2016 Apr; 12(2):91.e1-7. PubMed ID: 26522772
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Wang K; Khaira D; Ali SM; Fisher HA; Mian B; Nazeer T; Elvin JA; Palma N; Yelensky R; Lipson D; Miller VA; Stephens PJ; Subbiah V; Pal SK
Cancer; 2016 Mar; 122(5):702-11. PubMed ID: 26651075
[TBL] [Abstract][Full Text] [Related]
35. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder.
van Oers JM; Adam C; Denzinger S; Stoehr R; Bertz S; Zaak D; Stief C; Hofstaedter F; Zwarthoff EC; van der Kwast TH; Knuechel R; Hartmann A
Int J Cancer; 2006 Sep; 119(5):1212-5. PubMed ID: 16570285
[TBL] [Abstract][Full Text] [Related]
36. FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma.
Zhou H; He F; Mendelsohn CL; Tang MS; Huang C; Wu XR
Sci Rep; 2016 May; 6():25596. PubMed ID: 27157475
[TBL] [Abstract][Full Text] [Related]
37. Utility of GATA-3 and Cytokeratin 5/6 Immunostains in Separating Condyloma Acuminatum Arising in the Urinary Tract From Non-Invasive Papillary Urothelial Carcinoma.
Montoya-Cerrillo D; Briski LM; Jorda M; Kryvenko ON
Int J Surg Pathol; 2022 May; 30(3):260-264. PubMed ID: 34665053
[No Abstract] [Full Text] [Related]
38. [Inverted papillary carcinoma].
Angulo JC; López JI; Toledo JD; Flores Corral N
Arch Esp Urol; 1993 Oct; 46(8):695-8. PubMed ID: 8311519
[TBL] [Abstract][Full Text] [Related]
39. A case of tubulocystic carcinoma simultaneously occurring with clear cell type renal cell carcinoma and micropapillary urothelial carcinoma of bladder.
Gönül II; Cakr A; Sözen S; Ataoglu O; Alkibay T
South Med J; 2009 Jul; 102(7):754-7. PubMed ID: 19488016
[TBL] [Abstract][Full Text] [Related]
40. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
van Oers JM; Zwarthoff EC; Rehman I; Azzouzi AR; Cussenot O; Meuth M; Hamdy FC; Catto JW
Eur Urol; 2009 Mar; 55(3):650-7. PubMed ID: 18584939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
